This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


BioCritica, Inc.

Drug Names(s): drotrecogin alfa

Description: Xigris (drotrecogin alfa (activated)) is a recombinant form of human activated Protein C. Activated protein C is a natural anticoagulant, which exerts its antithrombotic effect by inactivating the activated form of factors V and VIII. It may also have indirect profibrinolytic activity through its ability to inhibit plasminogen activator inhibitor-1 (PAI-1) and may exert an anti-inflammatory effect by limiting the chemotactic response of leukocytes to inflammatory cytokines, an inhibitory process mediated by leukocyte cell surface activated Protein C receptor. In addition, in vivo data suggest activated Protein C may reduce interactions between leukocytes and the microvascular endothelium.

Deal Structure: In May 2005, the U.S. District Court of Massachusetts in Boston issued a decision that U.S. Patent No. 6,410,516, owned by Harvard, the Massachusetts Institute of Technology, and the Whitehead Institute and licensed to AriadPharmaceuticals, is valid and infringed by Lilly's sale of Evista and Xigris. The jury awarded the plaintiffs approximately $65 million in back royalties and a 2.3 percent royalty on future U.S. sales of Evista and Xigris until the patent's expiration.

Eli Lilly & Company and BioCritica, Inc.
In May 2011, Eli Lilly and Company announced that it has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica Inc., a newly-formed and privately-held biotechnology company.

As part of a licensing agreement, BioCritica will acquire the U.S. development and commercialization rights to Xigris and will also receive the rights to potentially acquire several critical care compounds currently in pre-clinical development...See full deal structure in Biomedtracker

Partners: ARIAD Pharmaceuticals, Inc. Eli Lilly & Company

Xigris News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug